Description

RT40 is a combined research formulation containing 20mg of Retatrutide and 40mg of Tirzepatide, providing 60mg of total peptide material. Retatrutide is investigated through GLP-1, GIP, and glucagon receptor pathways, while Tirzepatide is studied through GLP-1 and GIP receptor signalling. This combination brings multiple incretin-related pathways together within a single research formulation, supporting investigations into metabolic signalling, glucose homeostasis, energy regulation, and receptor activity. The formulation provides researchers with a specialised material for controlled laboratory studies exploring multi-receptor peptide interactions and metabolic pathways. RT40 contains 60mg total peptide material as specified and is intended for research purposes only.